Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.77 |
| ▸ | ENPP2 | Q13822 | 12/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5455256 | 0.94 | FAAH (0.68) | FAAHENPP2MEN1KMT2ALMNA | |
| SCHEMBL5451937 | 0.87 | FAAH (1.00) | FAAHENPP2LMNASMN1; SMN2 | |
| SCHEMBL5453555 | 0.87 | FAAH (0.66) | FAAHMEN1KMT2ASMN1; SMN2CHRM4 | |
| SCHEMBL5451896 | 0.86 | FAAH (0.65) | FAAHMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL5453621 | 0.83 | FAAH (0.70) | FAAHMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL5447729 | 0.81 | FAAH (0.88) | FAAHENPP2LMNASMN1; SMN2 | |
| SCHEMBL5450845 | 0.81 | FAAH (0.58) | FAAHMEN1KMT2ASMN1; SMN2CHRM4 | |
| SCHEMBL2175558 | 0.80 | FAAH (0.50) | FAAHMEN1KMT2A | |
| SCHEMBL5451889 | 0.80 | FAAH (0.57) | FAAHENPP2MEN1KMT2ALMNA | |
| SCHEMBL5447919 | 0.79 | FAAH (0.56) | FAAHENPP2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100549012-C | Aryl-and heteroaryl-piperidinecarboxylic acid derivatives, their preparation and use as FAAH enzyme inhibitors | SANOFI AVENTIS (FR) | 2009-10-14 | — | — | CN | disclosed |
| CN-1922177-A | Aryl-and heteroaryl-piperidinecarboxylic acid derivatives, their preparation and use as FAAH enzyme inhibitors | SANOFI AVENTIS (FR) | 2007-02-28 | — | — | CN | disclosed |
| US-20070021405-A1 | ARYL- AND HETEROARYLPIPERIDINECARBOXYLATE-DERIVATIVES METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021405-A1 | ARYL- AND HETEROARYLPIPERIDINECARBOXYLATE-DERIVATIVES METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | FAAH, FAAH2, HRH2 | FAAH 1/4885ENPP2 14/4885MEN1 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.